Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other pharma stocks. Healthcare takes the concept of ‘defensive’ further than almost ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2024 investor ...

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

Please go ahead. Thank you, Paul, and good morning, everybody. Thanks for joining us for Eli Lilly and Company's Q3 2024 earnings call. I'm Joe Fletcher, Senior Vice President of Investor Relations.

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

Eli Lilly has dropped (PDF) the lead candidate from its $2.4 billion takeover of Dice Thera | Eli Lilly has dropped the lead candidate from its $2.4 billion takeover of Dice Therapeutics, shifting the ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Eli Lilly executives insisted that underlying demand for the medicines remained strong and that the company has enough supply available. The reason for the disappointing sales, according to the ...

Its weight-loss drugs were removed from the FDA's shortage list during the quarter, while the company launched lower-cost single-use vials of Zepbound. As pharmaceutical giant Eli Lilly (LLY ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

Please go ahead. Thank you, Paul, and good morning, everybody. Thanks for joining us for Eli Lilly and company's Q3 2024 earnings call. I'm Joe Fletcher, Senior Vice President of Investor Relations.